PTC THERAPEUTICS, INC. (PTCT) — SEC Financial Statements & Analysis

PTC THERAPEUTICS, INC. (PTCT) is a pharmaceutical preparations company, incorporated in DE. PTC THERAPEUTICS, INC. trades on Nasdaq as: PTCT. PTC THERAPEUTICS, INC. (PTCT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30. Based on that filing, PTC THERAPEUTICS, INC. carries a market cap of $6.77B, a P/E ratio of -176.41x, a P/B ratio of -40.95x, a P/S ratio of 6.71x, an enterprise value of $6.30B, and an EV/EBITDA multiple of 34.83x. On profitability, it posts an operating margin of 12.45%, a net margin of -3.80%, a Return on Equity (ROE) of 20.64%, and a Return on Assets (ROA) of -1.30%. Per share, it reports EPS of $-0.46, diluted EPS of $-0.42, free cash flow per share of $-0.48, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -42.84% year-over-year, net income growth of -106.10% year-over-year, and EPS growth of -105.74% year-over-year. On the balance sheet, it maintains a current ratio of 3.39x, a quick ratio of 3.20x, working capital of $1.85B, a debt-to-equity ratio of -20.66x, a debt ratio of 1.05, an interest coverage ratio of 0.68x, free cash flow of $-39.78M (TTM), and net debt of $-469.36M. Figures sourced from SEC EDGAR.

Market Cap

$6.77B

P/E TTM

-176.41x

EPS TTM

$-0.46

P/B TTM

-40.95x

ROE TTM

20.64%

ROA TTM

-1.30%

Debt To Equity

-20.66x

Free Cash Flow TTM

$-39.78M

Net Revenue TTM Growth 1Y

-42.84%

Data as of 2026-06-30 · Source: SEC EDGAR